ArticleCancer medicine2026
The Role of Enterococcus faecium in the Synergistic Clearance of High-Risk HPV: A Clinical Study on Cervicovaginal Microbiota Regulation.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between vaginal microecological dysfunction and cervical lesion severity in postmenopausal women: a retrospective study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPersistent infection with high-risk human papillomavirus (HR-HPV) is defined as the principal cause of cervical cancer. Given the important role of cervicovaginal microbiota in HPV acquisition and disease progression, this study aims to evaluate the clinical efficacy of the probiotic Enterococcus faecium (E. faecium) in synergistically promoting clearance of persistent HR-HPV infection.
methodsWe conducted a prospective clinical study involving 365 female patients with persistent HR-HPV infection. Following necessary anti-infective treatment, participants were allocated by their preference to one of three groups: an intervention group receiving E. faecium supplementation (n = 124), a regular follow-up group (n = 120), or a blank control group (n = 121). Their HR-HPV status and microecological parameters were assessed at 0, 6, and 12 months. Additionally, 24 participants were selected for 16S rRNA sequencing to analyze changes in the cervicovaginal microbiota composition during the follow-up period.
resultsSupplementation with E. faecium resulted in a significantly higher HPV clearance rate compared to the regular follow-up and control groups (55.65% vs. 29.17% vs. 13.22%, p < 0.001). Multivariate analysis confirmed that smoking (OR = 0.110, 95% CI 0.014-0.857, p = 0.035) and duration of persistent HPV infection (OR = 0.872, 95% CI 0.794-0.958, p = 0.004) were independent factors affecting HPV clearance. In the experimental group, the ecological shift was evidenced by a marked increase in the abundance of Lactobacillus (from 54.01% to 75.65%) and a significant reduction in several pathobionts, including Atopobium, Prevotella, and Staphylococcus (p < 0.001). Importantly, the abundance of Lactobacillus was substantially higher in HPV-negative individuals than in those with persistent infection (93.78% vs. 29.96%, p < 0.001).
conclusionOur findings indicate that in women with persistent HR-HPV infection, E. faecium supplementation was associated with higher rates of HPV negativity and a shift toward a Lactobacilli-dominated vaginal microbiota, although causal relationships and underlying mechanisms require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.